1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2020, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 13, 3, 2, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Allergic Rhinitis - Overview
- Allergic Rhinitis - Therapeutics Development
- Allergic Rhinitis - Therapeutics Assessment
- Allergic Rhinitis - Companies Involved in Therapeutics Development
- Allergic Rhinitis - Drug Profiles
- Allergic Rhinitis - Dormant Projects
- Allergic Rhinitis - Discontinued Products
- Allergic Rhinitis - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Critical Limb Ischemia, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Companies, H2 2020 (Contd..2), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Critical Limb Ischemia - Pipeline by Ambulero Inc, H2 2020
- Critical Limb Ischemia - Pipeline by Anaeropharma Science Inc, H2 2020
- Critical Limb Ischemia - Pipeline by Antidote Therapeutics Inc, H2 2020
- Critical Limb Ischemia - Pipeline by apceth Biopharma GmbH, H2 2020
- Critical Limb Ischemia - Pipeline by Athersys Inc, H2 2020
- Critical Limb Ischemia - Pipeline by BiogenCell Ltd, H2 2020
- Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H2 2020
- Critical Limb Ischemia - Pipeline by Constant Therapeutics LLC, H2 2020
- Critical Limb Ischemia - Pipeline by Cynata Therapeutics Ltd, H2 2020
- Critical Limb Ischemia - Pipeline by Gurus BioPharm, H2 2020
- Critical Limb Ischemia - Pipeline by Helixmith Co Ltd, H2 2020
- Critical Limb Ischemia - Pipeline by Hemostemix Inc, H2 2020
- Critical Limb Ischemia - Dormant Projects, H2 2020
- Critical Limb Ischemia - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Critical Limb Ischemia, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Targets, H2 2020
- Number of Products by Stage and Targets, H2 2020
- Number of Products by Mechanism of Actions, H2 2020
- Number of Products by Stage and Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ambulero Inc
- Anaeropharma Science Inc
- Antidote Therapeutics Inc
- apceth Biopharma GmbH
- Athersys Inc
- BiogenCell Ltd
- Caladrius Biosciences Inc
- Constant Therapeutics LLC
- Cynata Therapeutics Ltd
- Gurus BioPharm
- Helixmith Co Ltd
- Hemostemix Inc
- ID Pharma Co Ltd
- Juventas Therapeutics Inc
- Kang Stem Biotech Co Ltd
- Libella Gene Therapeutics
- LifeCells LLC
- Nissan Chemical Corp
- Pharmicell Co Ltd
- Pluristem Therapeutics Inc
- ReNeuron Group Plc
- Reven Pharmaceuticals Inc
- Rexgenero Ltd
- TaiGen Biotechnology Co Ltd
- Taiwan Bio Therapeutics Co Ltd
- Theratome Bio Inc
- U.S. Stem Cell Inc
- VESSL Therapeutics Ltd
- Vivazome Therapeutics Pty Ltd
- Yichang Humanwell Pharmaceutical Co Ltd
